Eliquis (apixaban) is a prescription anticoagulant medication used to prevent blood clots in people with atrial fibrillation, deep vein thrombosis, and pulmonary embolism. It is one of the most widely prescribed anticoagulants, and is considered to be an effective and safe treatment option for many patients. However, there are potential risks associated with Eliquis, particularly in the elderly population. This article will discuss the potential risks of Eliquis in the elderly, including side effects, potential interactions with other medications, and the importance of monitoring for adverse reactions.
Eliquis is a direct factor Xa inhibitor, which works by blocking the action of factor Xa, a protein involved in the clotting process. This helps to prevent the formation of blood clots, which can cause serious health problems such as stroke, heart attack, and pulmonary embolism. Eliquis is generally well-tolerated, but it is important to be aware of the potential risks associated with taking this medication.
The elderly population is particularly vulnerable to the side effects of Eliquis. Common side effects of Eliquis include nausea, headache, dizziness, and fatigue. Elderly patients may also be more likely to experience bleeding, including bleeding from the nose, gums, or rectum, as well as bruising more easily. In some cases, Eliquis can also cause anemia, which can lead to fatigue and shortness of breath.
Eliquis can interact with other medications, including non-steroidal anti-inflammatory drugs (NSAIDs), aspirin, and other anticoagulants. It is important to discuss all medications that a patient is taking with their doctor, as some medications may increase the risk of bleeding or other side effects when taken with Eliquis.
It is important for elderly patients taking Eliquis to be monitored closely for any adverse reactions, such as bleeding or bruising. Patients should also be aware of the signs and symptoms of anemia, such as fatigue and shortness of breath. Regular blood tests should be done to monitor for any changes in the blood.
Eliquis is a widely prescribed anticoagulant medication used to prevent blood clots in people with atrial fibrillation, deep vein thrombosis, and pulmonary embolism. While Eliquis is generally well-tolerated, there are potential risks associated with taking this medication, particularly in the elderly population. It is important to be aware of the potential side effects of Eliquis, as well as any potential interactions with other medications. Regular monitoring for adverse reactions is also important, as this can help to detect any problems early and reduce the risk of serious complications.
1.
Use of social media during pregnancy may increase depression.
2.
Does diabetes impact the prognosis of people with colorectal cancer?
3.
Can the way we talk about cancer change how we interact with the disease?
4.
A higher risk of chemotherapy-induced peripheral neuropathy is associated with a deficiency in vitamin D prior to treatment.
5.
The biology of cancer as well as potential treatment options are examined by experts.
1.
What Is A Normal Fibrinogen Level, And How Can It Affect Your Health
2.
Exploring New Solutions for MCV Low: Unlocking the Potential for Improved Health
3.
Revolutionizing Cancer Care: The Promise of Early Detection and Biomarkers
4.
What You Need to Know About Correcting Calcium Levels in Patients with Low Albumin
5.
The benefits and risks of taking fludrocortisone for adrenal insufficiency
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
3.
Efficient Management of First line ALK-rearranged NSCLC - Part III
4.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion III
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation